Findings

What do systematic reviews say?

1 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Natalizumab · relapsing multiple sclerosis

It is very uncertain whether rituximab as 'switching' changes natalizumab compared with other disease‐modifying treatments (very low certainty).

2 findings from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
HR 1 [0.2, 5]
153 participants
Very low
Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
HR 0.24 [0.06, 1]
170 participants
Low